Cargando…
Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis
Sarcopenia is a major public health issue that affects older adults. Myostatin inhibitory-D-peptide-35 (MID-35) can increase skeletal muscle and is a candidate therapeutic agent, but a non-invasive and accessible technology for the intramuscular delivery of MID-35 is required. Recently, we succeeded...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058260/ https://www.ncbi.nlm.nih.gov/pubmed/36986496 http://dx.doi.org/10.3390/ph16030397 |
_version_ | 1785016582944063488 |
---|---|
author | Michiue, Kohki Takayama, Kentaro Taniguchi, Atsuhiko Hayashi, Yoshio Kogure, Kentaro |
author_facet | Michiue, Kohki Takayama, Kentaro Taniguchi, Atsuhiko Hayashi, Yoshio Kogure, Kentaro |
author_sort | Michiue, Kohki |
collection | PubMed |
description | Sarcopenia is a major public health issue that affects older adults. Myostatin inhibitory-D-peptide-35 (MID-35) can increase skeletal muscle and is a candidate therapeutic agent, but a non-invasive and accessible technology for the intramuscular delivery of MID-35 is required. Recently, we succeeded in the intradermal delivery of various macromolecules, such as siRNA and antibodies, by iontophoresis (ItP), a non-invasive transdermal drug delivery technology that uses weak electricity. Thus, we expected that ItP could deliver MID-35 non-invasively from the skin surface to skeletal muscle. In the present study, ItP was performed with a fluorescently labeled peptide on mouse hind leg skin. Fluorescent signal was observed in both skin and skeletal muscle. This result suggested that the peptide was effectively delivered to skeletal muscle from skin surface by ItP. Then, the effect of MID-35/ItP on skeletal muscle mass was evaluated. The skeletal muscle mass increased 1.25 times with ItP of MID-35. In addition, the percentage of new and mature muscle fibers tended to increase, and ItP delivery of MID-35 showed a tendency to induce alterations in the levels of mRNA of genes downstream of myostatin. In conclusion, ItP of myostatin inhibitory peptide is a potentially useful strategy for treating sarcopenia. |
format | Online Article Text |
id | pubmed-10058260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100582602023-03-30 Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis Michiue, Kohki Takayama, Kentaro Taniguchi, Atsuhiko Hayashi, Yoshio Kogure, Kentaro Pharmaceuticals (Basel) Article Sarcopenia is a major public health issue that affects older adults. Myostatin inhibitory-D-peptide-35 (MID-35) can increase skeletal muscle and is a candidate therapeutic agent, but a non-invasive and accessible technology for the intramuscular delivery of MID-35 is required. Recently, we succeeded in the intradermal delivery of various macromolecules, such as siRNA and antibodies, by iontophoresis (ItP), a non-invasive transdermal drug delivery technology that uses weak electricity. Thus, we expected that ItP could deliver MID-35 non-invasively from the skin surface to skeletal muscle. In the present study, ItP was performed with a fluorescently labeled peptide on mouse hind leg skin. Fluorescent signal was observed in both skin and skeletal muscle. This result suggested that the peptide was effectively delivered to skeletal muscle from skin surface by ItP. Then, the effect of MID-35/ItP on skeletal muscle mass was evaluated. The skeletal muscle mass increased 1.25 times with ItP of MID-35. In addition, the percentage of new and mature muscle fibers tended to increase, and ItP delivery of MID-35 showed a tendency to induce alterations in the levels of mRNA of genes downstream of myostatin. In conclusion, ItP of myostatin inhibitory peptide is a potentially useful strategy for treating sarcopenia. MDPI 2023-03-06 /pmc/articles/PMC10058260/ /pubmed/36986496 http://dx.doi.org/10.3390/ph16030397 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Michiue, Kohki Takayama, Kentaro Taniguchi, Atsuhiko Hayashi, Yoshio Kogure, Kentaro Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis |
title | Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis |
title_full | Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis |
title_fullStr | Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis |
title_full_unstemmed | Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis |
title_short | Increasing Skeletal Muscle Mass in Mice by Non-Invasive Intramuscular Delivery of Myostatin Inhibitory Peptide by Iontophoresis |
title_sort | increasing skeletal muscle mass in mice by non-invasive intramuscular delivery of myostatin inhibitory peptide by iontophoresis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058260/ https://www.ncbi.nlm.nih.gov/pubmed/36986496 http://dx.doi.org/10.3390/ph16030397 |
work_keys_str_mv | AT michiuekohki increasingskeletalmusclemassinmicebynoninvasiveintramusculardeliveryofmyostatininhibitorypeptidebyiontophoresis AT takayamakentaro increasingskeletalmusclemassinmicebynoninvasiveintramusculardeliveryofmyostatininhibitorypeptidebyiontophoresis AT taniguchiatsuhiko increasingskeletalmusclemassinmicebynoninvasiveintramusculardeliveryofmyostatininhibitorypeptidebyiontophoresis AT hayashiyoshio increasingskeletalmusclemassinmicebynoninvasiveintramusculardeliveryofmyostatininhibitorypeptidebyiontophoresis AT kogurekentaro increasingskeletalmusclemassinmicebynoninvasiveintramusculardeliveryofmyostatininhibitorypeptidebyiontophoresis |